Table 2.
Ref. | Type of study | No. Patients | Success rate | Follow-up (mo) |
Johnson et al[41] | Prospective | 15 | 87% | 7 |
Non-randomized | ||||
Controlled trial | ||||
Champagne et al[44] | Prospective | 46 | 83% | 12 |
O’Connor et al[45] | Prospective | 20 (Crohn’s) | 80% | 10 |
Van Koperen et al[46] | Prospective | 17 | 42% | 7 |
Ellis[47] | Retrospective | 18 (5 rectovaginal) | 88% | 6 |
Lawes et al[48] | Retrospective | 17 plug | 66% | 7.4 |
3 pug+flap | ||||
Ky et al[49] | Prospective | 44 plug+flap | 54.6% | 6.5 |
Schwandner et al[50] | Prospective | 19 (7 Crohn’s) | 61% overall | 9 |
45.5% cryptoglandular | ||||
85.7% Crohn’s | ||||
Garg[51] | Prospective | 21 | 71% | 10 |
Christoforidis et al[52] | Retrospective | 47 | 43% | 6.5 |
Thekkinkattil et al[53] | Prospective | 43 | 44% | 11 |
Safar et al[54] | Retrospective | 35 | 14% | 4 |
Ortiz et al[55] | Prospective Randomized trial | 31 cryptoglandular: -15 plug -16 endorectal-advancement flap (EAF) | 20% (plug group) 87.5% (EAF) | 12 |
El-Gazzaz et al[56] | Retrospective | 33 | 25% | 7.4 |
Chan et al[57] | Prospective | 44 | 50% | 10.5 |
Cintron et al[58] | Prospective | 73 | 42.5% | 15 |